Agios Pharmaceuticals, Inc. Earnings

Agios Pharmaceuticals, Inc.’s revenue jumped 44.57% since last year same period to $12.46Mn in the Q2 2025. On a quarterly growth basis, Agios Pharmaceuticals, Inc. has generated 42.73% jump in its revenue since last 3-months.

Agios Pharmaceuticals, Inc.’s net profit fell -16.54% since last year same period to $-112.02Mn in the Q2 2025. On a quarterly growth basis, Agios Pharmaceuticals, Inc. has generated -25.46% fall in its net profits since last 3-months.

Agios Pharmaceuticals, Inc.’s net profit margin jumped 19.39% since last year same period to -899.4% in the Q2 2025. On a quarterly growth basis, Agios Pharmaceuticals, Inc. has generated 12.1% jump in its net profit margins since last 3-months.

Agios Pharmaceuticals, Inc.’s price-to-earnings ratio after this Q2 2025 earnings stands at 3.41.

Agios Pharmaceuticals, Inc.’s earning per share (EPS) estimates for the current quarter stand at -1.91 - a -5.52% fall from last quarter’s estimates.

Agios Pharmaceuticals, Inc.’s earning per share (EPS) estimates for the current year stand at -1.91.

Agios Pharmaceuticals, Inc.’s earning per share (EPS) jumped 100% since last year same period to 0 in the Q3 2025. This indicates that the Agios Pharmaceuticals, Inc. has generated 100% annual rate of jump in its earning per share (EPS) in the last 4 quarters.